Received Jan 22, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 2 | — | — |
8 cm mass diagnosed with soft tissue sarcoma; one stent placed in the heart; Peripheral Artery Disease; three stents placed in the right leg artery; Pains starting in the right leg and lower back; Pains starting in the right leg and lower back; This is a spontaneous report received from a Consumer or other non HCP. A patient (age and gender not provided) received BNT162b2 (BNT162B2), in 2021 as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "COVID-19 infection", start date: Dec2020 (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE), administration date: 2021, for Covid-19 immunization. The following information was reported: BACK PAIN (non-serious), PAIN IN EXTREMITY (non-serious) all with onset Sep2021, outcome "unknown" and all described as "Pains starting in the right leg and lower back"; PERIPHERAL ARTERIAL OCCLUSIVE DISEASE (non-serious) with onset Jan2023, outcome "unknown", described as "Peripheral Artery Disease"; STENT PLACEMENT (non-serious) with onset Jan2023, outcome "unknown", described as "three stents placed in the right leg artery"; CORONARY ARTERIAL STENT INSERTION (non-serious) with onset Feb2023, outcome "unknown", described as "one stent placed in the heart"; SOFT TISSUE SARCOMA (medically significant) with onset Nov2023, outcome "unknown", described as "8 cm mass diagnosed with soft tissue sarcoma". The patient underwent the following laboratory tests and procedures: Angiogram: (21Aug2025) occluded stents were reopened; (Feb2023) one stent placed in the heart; Blood glucose: (unspecified date) 600 mg/dl, notes: on Anlotinib; Blood pressure measurement: (unspecified date) 170/100, notes: on Anlotinib; Blood test: (unspecified date) elevated D-Dimer; C-reactive protein: (unspecified date) high; (Sep2025) high; Culture: (03Sep2025) Unknown results, notes: was performed due to CSF leakage; (Sep2025) no growth but high CRP led to infection treatment; cfDNA: (16Nov2023) Unknown results, notes: Cell-free DNA, peripheral blood; (19May2024) Unknown results, notes: Soft tissue, retroperitoneal region; Tumor Samples: (06Nov2023) 70 %, notes: Lymph node, retroperitoneum; (01Oct2024) 60 %, notes: Peritoneum; (28Feb2025) 70 %, notes: Soft tissue; Pathology test: (01Oct2024) Unknown results, notes: 1. Lymph nodes (right iliac artery vicinity, 2): sarcomatous malignant tumor metastasis; additional 2 lymph nodes: reactive changes; (28Feb2025) Undifferentiated pleomorphic sarcoma.; (19Apr2025) Pleomorphic liposarcoma metastasis.; (08Sep2025) Consistent with pleomorphic liposarcoma metastasis; Positron emission tomogram: (Nov2023) 8 cm mass pressing on nerve roots in the spinal, notes: region detected by PETCT; diagnosed as soft tissue sarcoma; (30Jun2025) progression in the disease; (30Jun2025) progression; (08Oct2025) progression; (unspecified date) a special vaccine is using experimentally has been, notes: shown to halt the progression of (redacted) advanced-stage cancer causing regression in some etastases and even restoring some to normal; (08Oct2025) Post-op changes; no pathologic uptake. Thoracic:, notes: Progression with larger/multiple right lung nodules (SUVmax up to 11.99) and consolidation (SUVmax 5.73); left lung stable/increased. Abdominopelvic: Significant progression in psoas/L5-invading masses (up to 45x20 mm and 40x25 mm, SUVmax up to 20.76); new/extended lesions; (03Jun2025) Intense FDG uptake in right iliac/stentadjacent, notes: areas (SUVmax up to 26.79), including 31x13 mm and 20x18 mm lesions; linear uptake at S1 level. Thoracic: Multiple small pulmonary nodules (SUVmax up to 2.62 right; up to 1.97 left, some cavitary); (30Jun2025) Progression in iliac/psoas lesions (SUVmax up to, notes: 18.91); stable/slightly increased sizes. Thoracic: Increased pulmonary nodule uptake (SUVmax up to 4.67 right; up to 2.88 left); (21Jul2025) New intense focal uptake in right occipital/, notes: cerebellar region (SUVmax 16.41). Thoracic: Increased pulmonary uptake (SUVmax up to 4.82 right; up to 3.88 left). Abdominopelvic: Stable iliac/psoas lesions with slightly lower SUVmax; (04Nov2025) No pathologic uptake. Thoracic: Slight decrease in, notes: some right lung SUVmax (main nodule 5.58); left lung increased (up to 7.33); new consolidations. Abdominopelvic: Further enlargement of anterior psoas mass (48x36 mm, SUVmax 20.98); stable/high uptake in other iliac/psoas areas; one prior LAP resolved. Additional information: Between July and August 2021, the patient received two doses of the BioNTech vaccine. In September 2021, the patient began experiencing pain in the right leg and lower back, which resulted in consultations with multiple physicians. In January 2023, the patient was diagnosed with peripheral artery disease, and three stents were placed in the artery of the right leg. In February 2023, a cardiac angiography was performed, and one stent was inserted in the heart. In November 2023, a PET-CT scan identified an approximately 8 cm mass compressing the nerve roots in the spinal region, and the patient was subsequently diagnosed with soft tissue sarcoma. Batch/lot number is not provided, and it cannot be obtained.
Medical History/Concurrent Conditions: COVID-19
Test Date: 20250821; Test Name: angiography; Result Unstructured Data: Test Result:occluded stents were reopened; Test Date: 202302; Test Name: Cardiac angiography; Result Unstructured Data: Test Result:one stent placed in the heart; Test Name: glucose; Test Result: 600 mg/dl; Comments: on Anlotinib; Test Name: BP; Result Unstructured Data: Test Result:170/100; Comments: on Anlotinib; Test Name: Blood tests; Result Unstructured Data: Test Result:elevated D-Dimer; Test Name: CRP; Result Unstructured Data: Test Result:high; Test Date: 202509; Test Name: CRP; Result Unstructured Data: Test Result:high; Test Date: 20250903; Test Name: culture test; Result Unstructured Data: Test Result:Unknown results; Comments: was performed due to CSF leakage; Test Date: 202509; Test Name: culture test; Result Unstructured Data: Test Result:no growth but high CRP led to infection treatment; Test Date: 20231116; Test Name: cfDNA; Result Unstructured Data: Test Result:Unknown results; Comments: Cell-free DNA, peripheral blood; Test Date: 20240519; Test Name: Tumor Samples; Result Unstructured Data: Test Result:Unknown results; Comments: Soft tissue, retroperitoneal region; Test Date: 20231106; Test Name: Tumor Samples; Test Result: 70 %; Comments: Lymph node, retroperitoneum; Test Date: 20241001; Test Name: Tumor Samples; Test Result: 60 %; Comments: Peritoneum; Test Date: 20250228; Test Name: Tumor Samples; Test Result: 70 %; Comments: Soft tissue; Test Date: 20241001; Test Name: Pathology; Result Unstructured Data: Test Result:Unknown results; Comments: 1. Lymph nodes (right iliac artery vicinity, 2): sarcomatous malignant tumor metastasis; additional 2 lymph nodes: reactive changes.; Test Date: 20250228; Test Name: Pathology; Result Unstructured Data: Test Result:Undifferentiated pleomorphic sarcoma.; Test Date: 20250419; Test Name: Pathology; Result Unstructured Data: Test Result:Pleomorphic liposarcoma metastasis.; Test Date: 20250908; Test Name: Pathology; Result Unstructured Data: Test Result:Consistent with pleomorphic liposarcoma metastasis; Test Date: 202311; Test Name: PET CT; Result Unstructured Data: Test Result:8 cm mass pressing on nerve roots in the spinal; Comments: region detected by PETCT; diagnosed as soft tissue sarcoma.; Test Date: 20250630; Test Name: PET CT; Result Unstructured Data: Test Result:progression in the disease; Test Date: 20250630; Test Name: PET CT; Result Unstructured Data: Test Result:progression; Test Date: 20251008; Test Name: PET CT; Result Unstructured Data: Test Result:progression; Test Name: PET SCAN; Result Unstructured Data: Test Result:a special vaccine is using experimentally has been; Comments: shown to halt the progression of (redacted) advanced-stage cancer causing regression in some etastases and even restoring some to normal.; Test Date: 20251008; Test Name: PET-CT (post-brain radiotherapy/surgery) Head/neck; Result Unstructured Data: Test Result:Post-op changes; no pathologic uptake. Thoracic:; Comments: Progression with larger/multiple right lung nodules (SUVmax up to 11.99) and consolidation (SUVmax 5.73); left lung stable/increased. Abdominopelvic: Significant progression in psoas/L5-invading masses (up to 45x20 mm and 40x25 mm, SUVmax up to 20.76); new/extended lesions.; Test Date: 20250603; Test Name: PET-CT Abdominopelvic; Result Unstructured Data: Test Result:Intense FDG uptake in right iliac/stentadjacent; Comments: areas (SUVmax up to 26.79), including 31x13 mm and 20x18 mm lesions; linear uptake at S1 level. Thoracic: Multiple small pulmonary nodules (SUVmax up to 2.62 right; up to 1.97 left, some cavitary).; Test Date: 20250630; Test Name: PET-CT Abdominopelvic; Result Unstructured Data: Test Result:Progression in iliac/psoas lesions (SUVmax up to; Comments: 18.91); stable/slightly increased sizes. Thoracic: Increased pulmonary nodule uptake (SUVmax up to 4.67 right; up to 2.88 left).; Test Date: 20250721; Test Name: PET-CT Head/neck; Result Unstructured Data: Test Result:New intense focal uptake in right occipital/; Comments: cerebellar region (SUVmax 16.41). Thoracic: Increased pulmonary uptake (SUVmax up to 4.82 right; up to 3.88 left). Abdominopelvic: Stable iliac/psoas lesions with slightly lower SUVmax.; Test Date: 20251104; Test Name: PET-CT Head/neck; Result Unstructured Data: Test Result:No pathologic uptake. Thoracic: Slight decrease in; Comments: some right lung SUVmax (main nodule 5.58); left lung increased (up to 7.33); new consolidations. Abdominopelvic: Further enlargement of anterior psoas mass (48x36 mm, SUVmax 20.98); stable/high uptake in other iliac/psoas areas; one prior LAP resolved.